Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study.
Axial Spondyloarthritis
Pain Catastrophizing
Psoriatic Arthritis
Retention Rate
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
received:
18
03
2024
accepted:
03
09
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
18
9
2024
Statut:
epublish
Résumé
Chronic pain and inflammation are common features of rheumatic conditions such as Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), often needing prolonged medication treatment for effective management. Maintaining drug retention is essential for both achieving disease control and improving patients' quality of life. This study investigates the influence of pain catastrophizing, a psychological response to pain, on the drug retention rates of PsA and axSpA patients. A two-year prospective multicenter observational study involved 135 PsA and 71 axSpA patients. Pain Catastrophizing Scale (PCS) was employed to assess pain catastrophizing. Univariable and multivariable regression analyses were utilized to identify factors associated with drug retention. In the PsA group, patients early discontinuing therapy showed higher baseline disease activity as well as higher incidence of comorbid fibromyalgia. Notably, pain catastrophizing, specifically the domains of Helplessness, Magnification, and Rumination, were significantly elevated in PsA patients who interrupted the treatment. Multivariable analysis confirmed pain catastrophizing as an independent predictor of drug suspension within two years. In axSpA, drug discontinuation was associated with female gender, shorter disease duration, higher baseline disease activity as well as elevated levels of pain catastrophizing. Univariable analysis supported the role of pain catastrophizing, including its domains, as predictors of treatment interruption. However, limited events in axSpA patients precluded a multivariate analysis. This prospective study emphasizes the impact of pain catastrophizing on drug retention in patients with PsA and axSpA.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic pain and inflammation are common features of rheumatic conditions such as Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), often needing prolonged medication treatment for effective management. Maintaining drug retention is essential for both achieving disease control and improving patients' quality of life. This study investigates the influence of pain catastrophizing, a psychological response to pain, on the drug retention rates of PsA and axSpA patients.
METHODS
METHODS
A two-year prospective multicenter observational study involved 135 PsA and 71 axSpA patients. Pain Catastrophizing Scale (PCS) was employed to assess pain catastrophizing. Univariable and multivariable regression analyses were utilized to identify factors associated with drug retention.
RESULTS
RESULTS
In the PsA group, patients early discontinuing therapy showed higher baseline disease activity as well as higher incidence of comorbid fibromyalgia. Notably, pain catastrophizing, specifically the domains of Helplessness, Magnification, and Rumination, were significantly elevated in PsA patients who interrupted the treatment. Multivariable analysis confirmed pain catastrophizing as an independent predictor of drug suspension within two years. In axSpA, drug discontinuation was associated with female gender, shorter disease duration, higher baseline disease activity as well as elevated levels of pain catastrophizing. Univariable analysis supported the role of pain catastrophizing, including its domains, as predictors of treatment interruption. However, limited events in axSpA patients precluded a multivariate analysis.
CONCLUSION
CONCLUSIONS
This prospective study emphasizes the impact of pain catastrophizing on drug retention in patients with PsA and axSpA.
Identifiants
pubmed: 39294672
doi: 10.1186/s13075-024-03396-5
pii: 10.1186/s13075-024-03396-5
doi:
Substances chimiques
Antirheumatic Agents
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
162Informations de copyright
© 2024. The Author(s).
Références
Dougados M, Baeten D. Spondyloarthritis. Lancet Lond Engl. 2011;377(9783):2127–37.
doi: 10.1016/S0140-6736(11)60071-8
FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis Nat Rev Dis Primer. 2021;7(1):59.
doi: 10.1038/s41572-021-00293-y
Haque N, Lories RJ, de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol. 2016;43(2):376–82.
doi: 10.3899/jrheum.141359
pubmed: 26669922
Scriffignano S, Perrotta FM, De Socio A, Lubrano E. Role of comorbidities in spondyloarthritis including psoriatic arthritis. Clin Rheumatol. 2019;38(1):3–10.
doi: 10.1007/s10067-018-4332-7
pubmed: 30338414
Navarini L, Caso F, Costa L, Currado D, Stola L, Perrotta F, et al. Cardiovascular risk prediction in ankylosing spondylitis: from traditional scores to machine learning assessment. Rheumatol Ther. 2020;7(4):867–82.
doi: 10.1007/s40744-020-00233-4
pubmed: 32939675
pmcid: 7695785
Navarini L, Margiotta DPE, Caso F, Currado D, Tasso M, Angeletti S, et al. Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE. 2018;13(10):e0205506.
doi: 10.1371/journal.pone.0205506
pubmed: 30308025
pmcid: 6181379
Caso F, Navarini L, Carubbi F, Picchianti-Diamanti A, Chimenti MS, Tasso M, et al. Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. Rheumatol Int. 2020;40(6):951–8.
doi: 10.1007/s00296-019-04458-7
pubmed: 31605152
Navarini L, Costa L, Tasso M, Chimenti MS, Currado D, Fonti GL, et al. Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clin Rheumatol. 2020;39(9):2663–70.
doi: 10.1007/s10067-020-05027-1
pubmed: 32189149
Linton SJ, Nicholas MK, MacDonald S, Boersma K, Bergbom S, Maher C, et al. The role of depression and catastrophizing in musculoskeletal pain. Eur J Pain Lond Engl. 2011;15(4):416–22.
doi: 10.1016/j.ejpain.2010.08.009
Quartana PJ, Campbell CM, Edwards RR. Pain catastrophizing: a critical review. Expert Rev Neurother. 2009;9(5):745–58.
doi: 10.1586/ern.09.34
pubmed: 19402782
pmcid: 2696024
Wilk M, Łosińska K, Pripp AH, Korkosz M, Haugeberg G. Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life. Rheumatol Int. 2022;42(4):669–82.
doi: 10.1007/s00296-021-05070-4
pubmed: 35098329
Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O’Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. J Behav Med. 1997;20(6):589–605.
doi: 10.1023/A:1025570508954
pubmed: 9429990
Currado D, Biaggi A, Pilato A, Marino A, Ruscitti P, Pantano I, et al. The negative impact of pain catastrophising on disease activity: analyses of data derived from patient-reported outcomes in psoriatic arthritis and axial spondyloarthritis. Clin Exp Rheumatol. 2023;41(9):1856–61.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–73.
doi: 10.1002/art.21972
pubmed: 16871531
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1–44.
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 2011;63(Suppl 11):S64-85.
Bazzichi L, Giacomelli C, Consensi A, Giorgi V, Batticciotto A, Di Franco M, et al. One year in review 2020: fibromyalgia. Clin Exp Rheumatol. 2020;38 Suppl 123(1):3–8.
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–29.
doi: 10.1016/j.semarthrit.2016.08.012
pubmed: 27916278
Armağan B, Kılıç L, Farisoğulları B, Yardımcı GK, Bilgin E, Bölek EÇ, et al. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis. Rheumatol Int. 2023;43(1):147–56.
doi: 10.1007/s00296-022-05213-1
pubmed: 36129541
Athanassiou P, Kotrotsios A, Kallitsakis I, Bounas A, Dimitroulas T, Garyfallos A, et al. The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the ‘GO-UP’ study. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2022;31(5):1385–99.
Ferrito M, Cincinelli G, Manara M, Di Taranto R, Favalli EG, Caporali R. Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients. Reumatismo. 2023;75(2).
Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1(1):e000181.
doi: 10.1136/rmdopen-2015-000181
pubmed: 26819748
pmcid: 4716450
Navarini L, Currado D, Pilato A, Marino A, Biaggi A, Di Donato S, et al. Association between Patient Acceptable Symptom State and disease activity in psoriatic arthritis is disrupted by confounders, including comorbid fibromyalgia. Clin Exp Rheumatol. 2024;42(6):1150–5.
Navarini L, Currado D, Caso F, Costa L, Chimenti MS, D’Antonio A, et al. Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clin Exp Rheumatol. 2022;40(7):1285–92.
pubmed: 34665697
Penhoat M, Saraux A, Le Goff B, Augereau P, Maugars Y, Berthelot JM. High pain catastrophizing scores in one-fourth of patients on biotherapy for spondylarthritis or rheumatoid arthritis. Joint Bone Spine. 2014;81(3):235–9.
doi: 10.1016/j.jbspin.2013.10.004
pubmed: 24321439
Hayashi K, Morishima T, Ikemoto T, Miyagawa H, Okamoto T, Ushida T, et al. Pain Catastrophizing is independently associated with quality of life in patients with severe hip osteoarthritis. Pain Med Malden Mass. 2019;20(11):2220–7.
Kieskamp SC, Paap D, Carbo MJG, Wink F, Bos R, Bootsma H, et al. Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis. Rheumatol Oxf Engl. 2021;60(10):4476–85.
doi: 10.1093/rheumatology/keab019
Craner JR, Gilliam WP, Sperry JA. Rumination, magnification, and helplessness: How do Different aspects of pain catastrophizing relate to pain severity and functioning? Clin J Pain. 2016;32(12):1028–35.
doi: 10.1097/AJP.0000000000000355
pubmed: 26783987
Generali E, Sciré CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. Isr Med Assoc J IMAJ. 2016;18(3–4):203–8.
pubmed: 27228644
Chimenti MS, Fonti GL, Conigliaro P, Sunzini F, Scrivo R, Navarini L, et al. One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. Expert Opin Biol Ther. 2020;20(7):813–21.
doi: 10.1080/14712598.2020.1761957
pubmed: 32401062
Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969.
doi: 10.1155/2014/862969
pubmed: 25110401
pmcid: 4119698
Favalli EG, Selmi C, Becciolini A, Biggioggero M, Ariani A, Santilli D, et al. Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis. Arthritis Care Res. 2017;69(6):867–74.
doi: 10.1002/acr.23090